“Anatomic Pathology Market Report is set to have rapid growth due rising implementation of tissue-diagnostic related procedures in disease screening and favourable reimbursement policies at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Anatomic Pathology Market Forecast 2019-2029: By Application (Disease Diagnosis, Drug Discovery & Development), By Product & Services (Instruments, Consumables), By End Use, And Segment Forecasts.

The global Anatomic Pathology market is poised for rapid growth between 2019 and 2029. The increase in the incidence of chronic diseases, advances in technology and the increase in the geriatric population are some of the key factors driving market growth.

Advances in technology have witnessed the anatomical pathology market. For example, in November 2018, Greg Clark, business secretary of the UK government, announced that the consortium groups will gather to create five new pathology and digital imaging centers, using artificial intelligence to accelerate the diagnosis of diseases in the United Kingdom, bringing together representatives of various divisions of the sector.

Companies are making continuous efforts to develop advanced and up-to-date pathological equipment with regards to their design and ease of use. Furthermore, there have been several collaborations and agreements between key companies for the introduction of an effective portfolio in order to circumvent the challenges related to disease management.

Leading companies featured in the report include Thermo Fisher Scientific, Inc.; Cardinal Health, Inc.; F. Hoffmann-La Roche AG; Agilent Technologies, Inc.; Sakura Finetek USA, Inc.; Quest Diagnostics Incorporated; Laboratory Corporation of America Holdings; NeoGenomics Laboratories, Inc.; BioGenex; and Bio SB.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever